494 related articles for article (PubMed ID: 25977232)
1. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
Jung E; Kim J; Ho Kim S; Kim S; Cho MH
Eur J Pharmacol; 2015 Aug; 761():116-24. PubMed ID: 25977232
[TBL] [Abstract][Full Text] [Related]
2. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.
Jung E; Kim J; Kim SH; Kim S; Cho MH
Eur J Pharmacol; 2014 Dec; 744():98-102. PubMed ID: 25448307
[TBL] [Abstract][Full Text] [Related]
3. The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
Moon JY; Woo JS; Seo JW; Lee A; Kim DJ; Kim YG; Kim SY; Lee KH; Lim SJ; Cheng XW; Lee SH; Kim W
PLoS One; 2016; 11(3):e0150745. PubMed ID: 26959365
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
5. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.
Susztak K; Raff AC; Schiffer M; Böttinger EP
Diabetes; 2006 Jan; 55(1):225-33. PubMed ID: 16380497
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation.
Choi SH; Park S; Oh CJ; Leem J; Park KG; Lee IK
Vascul Pharmacol; 2015 Oct; 73():11-9. PubMed ID: 26187356
[TBL] [Abstract][Full Text] [Related]
8. Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
Choi SH; Leem J; Lee IK
Mediators Inflamm; 2017; 2017():4139439. PubMed ID: 29317794
[TBL] [Abstract][Full Text] [Related]
9. DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury.
Zhang L; Zhang Q; Liu S; Chen Y; Li R; Lin T; Yu C; Zhang H; Huang Z; Zhao X; Tan X; Li Z; Ye Z; Ma J; Zhang B; Wang W; Shi W; Liang X
Kidney Int; 2017 Jul; 92(1):140-153. PubMed ID: 28318634
[TBL] [Abstract][Full Text] [Related]
10. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.
Zhang M; Liu M; Xiong M; Gong J; Tan X
J Ethnopharmacol; 2012 May; 141(1):111-8. PubMed ID: 22353431
[TBL] [Abstract][Full Text] [Related]
11. DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury.
Eun Lee J; Kim JE; Lee MH; Song HK; Ghee JY; Kang YS; Min HS; Kim HW; Cha JJ; Han JY; Han SY; Cha DR
Lab Invest; 2016 May; 96(5):547-60. PubMed ID: 26878135
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy.
Advani A; Wiggins KJ; Cox AJ; Zhang Y; Gilbert RE; Kelly DJ
Nephrology (Carlton); 2011 Aug; 16(6):573-81. PubMed ID: 21342330
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.
Loeffler I; Rüster C; Franke S; Liebisch M; Wolf G
Am J Physiol Renal Physiol; 2013 Sep; 305(6):F911-8. PubMed ID: 23825071
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet-mediated activation of the CaMKKβ-LKB1-AMPK pathway attenuates diabetic nephropathy in db/db mice by modulation of apoptosis and autophagy.
Lim JH; Kim HW; Kim MY; Kim TW; Kim EN; Kim Y; Chung S; Kim YS; Choi BS; Kim YS; Chang YS; Kim HW; Park CW
Cell Death Dis; 2018 Feb; 9(3):270. PubMed ID: 29449563
[TBL] [Abstract][Full Text] [Related]
16. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.
Zhang L; Li R; Shi W; Liang X; Liu S; Ye Z; Yu C; Chen Y; Zhang B; Wang W; Lai Y; Ma J; Li Z; Tan X
Br J Pharmacol; 2013 Sep; 170(2):426-39. PubMed ID: 23826864
[TBL] [Abstract][Full Text] [Related]
17. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.
Chen J; Chen Y; Luo Y; Gui D; Huang J; He D
Eur J Pharmacol; 2014 Aug; 736():86-94. PubMed ID: 24809932
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
Kubo A; Hidaka T; Nakayama M; Sasaki Y; Takagi M; Suzuki H; Suzuki Y
BMC Nephrol; 2020 Sep; 21(1):402. PubMed ID: 32948146
[TBL] [Abstract][Full Text] [Related]
19. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis.
Zhou LL; Cao W; Xie C; Tian J; Zhou Z; Zhou Q; Zhu P; Li A; Liu Y; Miyata T; Hou FF; Nie J
Kidney Int; 2012 Oct; 82(7):759-70. PubMed ID: 22622498
[TBL] [Abstract][Full Text] [Related]
20. Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis.
Herbach N; Schairer I; Blutke A; Kautz S; Siebert A; Göke B; Wolf E; Wanke R
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F819-29. PubMed ID: 19211686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
